

RAPID COMMUNICATION

## *H. pylori* eradication: A randomized prospective study of triple therapy with or without ecabet sodium

Hyung Wook Kim, Gwang Ha Kim, Jong Yun Cheong, Ung Suk Yang, Seung Keun Park, Chul Soo Song, Dae Hwan Kang, Geun Am Song

Hyung Wook Kim, Ung Suk Yang, Department of Internal Medicine, Bongseng Memorial Hospital, Busan, Korea

Gwang Ha Kim, Jong Yun Cheong, Chul Soo Song, Dae Hwan Kang, Geun Am Song, Department of Internal Medicine, Pusan National University School of Medicine, Busan 602-739, Korea

Seung Keun Park, Department of Internal Medicine, Maryknoll Hospital, Busan, Korea

**Author contributions:** Kim HW and Kim GH contributed equally to this work; Kim GH, Cheong JY and Song GA designed the research; Kim HW, Kim GH, Cheong JY, Yang US, Park SK and Song CS performed the research; Kim GH, and Kang DH analyzed the data; and Kim HW and Kim GH wrote the paper.

**Supported by** An unrestricted grant by JEIL Pharm. Co., Ltd., Korea

**Correspondence to:** Gwang Ha Kim, Department of Internal Medicine, Pusan National University School of Medicine and Medical Research Institute, Pusan National University Hospital, 1-10 Ami-dong, Seo-Gu, Busan 602-739, Korea. [doc0224@pusan.ac.kr](mailto:doc0224@pusan.ac.kr)

Telephone: +82-51-2407869 Fax: +82-51-2448180  
Received: September 14, 2007 Revised: November 22, 2007

triple therapy for *H. pylori*.

© 2008 WJG. All rights reserved.

**Key words:** *H. pylori*; Eradication; Triple therapy; Ecabet sodium

**Peer reviewers:** Reza Malekzadeh, Professor, Director, Digestive Disease Research Center, Tehran University of Medical Sciences, Shariati Hospital, Kargar Shomali Avenue, 19119 Tehran, Iran; Bruno Annibale, Professor, Digestive and Liver Disease Unit, University "La Sapienza" II School of Medicine, Via di Grottarossa 1035, Roma 00189, Italy; Frank I Tovey, OBE, ChM, FRCS, Honorary Research Fellow, Department of Surgery, University College London, London, United Kingdom

Kim HW, Kim GH, Cheong JY, Yang US, Park SK, Song CS, Kang DH, Song GA. *H. pylori* eradication: A randomized prospective study of triple therapy with or without ecabet sodium. *World J Gastroenterol* 2008; 14(6): 908-912 Available from: URL: <http://www.wjgnet.com/1007-9327/14/908.asp> DOI: <http://dx.doi.org/10.3748/wjg.14.908>

### Abstract

**AIM:** To investigate whether adding ecabet sodium to the standard triple therapy for *H. pylori* infection improve eradication rate.

**METHODS:** Two hundred and fifty-seven *H. pylori*-infected patients were randomly assigned to standard triple therapy (group A,  $n = 129$ ) or triple therapy plus ecabet sodium (group B,  $n = 128$ ). Successful eradication was defined as a negative  $^{13}\text{C}$ -urea breath test 6-8 wk after completion of treatment.

**RESULTS:** After completion of therapy, 194/257 patients showed negative  $^{13}\text{C}$ -urea breath test results. According to intention-to-treat analysis, the infection was eradicated in 93/129 (72.1%) patients in group A and 101/128 (78.9%) in group B ( $P = 0.204$ ). Per-protocol analysis showed successful eradication in 93/118 (78.8%) patients from group A and 101/114 (88.6%) from group B ( $P = 0.044$ ). There were no significant differences in the side effects experienced by the patients in the two treatment groups.

**CONCLUSION:** Our results suggest that the addition of ecabet sodium improves the efficacy of the standard

### INTRODUCTION

*H. pylori* is a gram-negative spiral-shaped bacterium that colonizes the human stomach and it is associated with several gastroduodenal diseases, including gastritis, peptic ulcer disease and low-grade gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Eradication of *H. pylori* is the recommended treatment for these conditions<sup>[1]</sup>. The most widely endorsed treatment is triple therapy with amoxicillin, clarithromycin and a proton pump inhibitor two times daily for 7 d, and the reported efficacy of this protocol is 74%-76%<sup>[2]</sup>. The reasons for its occasional failure are unclear, although bacterial resistance and poor patient compliance are believed to be the primary factors<sup>[3]</sup>. Ecabet sodium is a dehydroabiatic acid derivative that was originally purified from pine resin<sup>[4]</sup>, which is now widely used for the treatment of gastric ulcer and gastritis in East Asia. This agent exhibits a bactericidal effect against *H. pylori* by inhibiting bacterial urease activity<sup>[5]</sup>, or by its direct bactericidal effect under acidic conditions<sup>[6,7]</sup>. Its bactericidal effect on clarithromycin- and metronidazole-resistant clinical isolates of *H. pylori* has been reported<sup>[7]</sup>. Therefore, ecabet sodium has been suggested to improve the efficacy of antibiotic therapy for *H. pylori* infection

in patients with peptic ulcer<sup>[8-12]</sup>. To the best of our knowledge, the efficacy and safety of standard triple therapy plus ecabet sodium has not yet been investigated. Therefore, the aim of this study was to compare the efficacy and side effects of standard triple therapy versus triple therapy plus ecabet sodium for the eradication of *H pylori*.

## MATERIALS AND METHODS

### Patients

This randomized prospective study was performed at three medical centers (Pusan National University Hospital, Bongseng Memorial Hospital and Maryknoll Hospital, Busan, Korea). The subjects consisted of 257 consecutive *H pylori*-positive patients who had undergone eradication therapy from May 2006 to April 2007. The criteria for exclusion included: (1) previous *H pylori* eradication therapy; (2) ingestion of antibiotics, bismuth, or proton pump inhibitors within the prior 4 wk; (3) patients with a history of allergy to the medications used; (4) patients with previous gastric surgery; (5) coexistence of serious concomitant illness (for example, decompensated liver cirrhosis or uremia); and (6) pregnant women.

All the participants were advised to undergo *H pylori* eradication therapy and they all agreed. There were 148 men and 109 women (mean age  $53.9 \pm 12.8$  years), and these included: 128 patients with gastric ulcer (or ulcer scar); 63 with duodenal ulcer (or ulcer scar); 14 with gastroduodenal ulcer (or ulcer scar); 12 who had received endoscopic treatment for early gastric cancer or adenoma; one with gastric low-grade MALT lymphoma; and 39 with gastritis accompanied by dyspepsia or a family history of gastric cancer (Table 1).

The patients were then randomized into two groups: group A ( $n = 129$ ) underwent standard triple therapy for 7 d (lansoprazole 30 mg b.i.d., clarithromycin 500 mg b.i.d. and amoxicillin 1 g b.i.d.), while group B ( $n = 128$ ) patients were given treatment consisting of the same triple therapy plus ecabet sodium (1.0 g b.i.d.) for a period of 7 d. Patients were instructed to take all the drugs 30 min after breakfast and dinner. This study was performed in accordance with good clinical practice and the Declaration of Helsinki guidelines. The Institutional Review Board of Pusan National University Hospital approved this study, and informed consent was obtained from all the patients.

### Methods

Before receiving therapy, all the patients underwent upper gastrointestinal endoscopy to confirm the diagnosis and the presence of *H pylori* infection. Positive *H pylori* status was confirmed by the rapid urease test, histology, serology (serum IgG antibody) and/or the <sup>13</sup>C-urea breath test. The patients were diagnosed as *H pylori*-positive when they showed positive results by at least two methods.

Possible eradication of *H pylori* was assessed by the <sup>13</sup>C-urea breath test at 6-8 wk after completion of treatment. Proton pump inhibitors and antimicrobial agents that might affect the <sup>13</sup>C-urea breath test were not given to the patients after completion of therapy.

**Table 1** Demographic data and endoscopic findings of 257 patients with *H pylori* infection who were randomly assigned to standard triple therapy (group A) or triple therapy plus ecabet sodium (group B)

	Group A	Group B	P value
Patients	129	128	
Age (yr) (mean $\pm$ SD)	54.3 $\pm$ 13.2	53.4 $\pm$ 12.4	0.562
Gender (male/female)	68/61	80/48	0.112
BMI (kg/m <sup>2</sup> ) (mean $\pm$ SD)	23.3 $\pm$ 2.9	23.2 $\pm$ 3.0	0.768
Smoking	32 (24.8%)	32 (25.0%)	0.971
Alcohol consumption	40 (31.0%)	56 (43.8%)	0.035
Endoscopic findings			0.333
Gastric ulcer	62	66	
Duodenal ulcer	37	26	
Gastroduodenal ulcer	8	6	
Gastric cancer <sup>1</sup>	7	5	
Gastric MALT lymphoma	0	1	
Gastritis	15	24	

<sup>1</sup>Patients who had received endoscopic treatment for early gastric cancer or adenoma.

The <sup>13</sup>C-urea breath test was performed as described previously, with capsule-based modification<sup>[13]</sup>. In brief, the patients fasted for over 12 h before examination and then a gelatin capsule containing 38 mg <sup>13</sup>C-urea was ingested with 50 mL water. Breath samples before and 20 min after administration of <sup>13</sup>C-urea were collected after a mouthwash. The <sup>13</sup>C/<sup>12</sup>C ratio in the breath samples was measured by mass spectrometry (Heliview; MediChems, Seoul, Korea). The changes in the <sup>13</sup>C value over baseline were expressed as  $\Delta^{13}\text{C}$ . A positive result was defined as an increase of  $> 2\%$ .


The eradication rate was evaluated for each drug regimen in a per-protocol (PP) analysis based on the number of patients who completed the study, and in an intention-to-treat (ITT) analysis that took into account all the patients, including those who dropped out because of severe side effects, those who showed poor drug compliance, and those who were lost to follow-up. The patients were interviewed in their first visit to the clinic after completion of therapy to clarify their compliance with the therapy and any side effects. Poor compliance was defined as taking less than 70% of the total medication.

### Statistical analysis

$\chi^2$  or Fisher's exact tests were used to compare the characteristics of the patients and the results of two regimens. Independent *t* tests were also employed to compare the possible differences in the age and body mass index of the patients who were treated with the two regimens.  $P < 0.05$  was considered statistically significant. Statistical calculations were performed using SPSS version 12.0 for Windows (SPSS, Chicago, IL, USA).

## RESULTS

Group A consisted of 129 patients (68 men and 61 women, mean age  $54.3 \pm 13.2$  years) and group B consisted of 128 patients (80 men and 48 women, mean age  $53.4 \pm 12.4$  years). Data regarding the clinical



**Figure 1** CONSORT flow diagram of the subjects' progress through the phases of the study.

characteristics of the patients at entry are summarized in Table 1. The two groups had a comparable age, gender and history of smoking. Alcohol consumption was more common in group B than in group A. There were no significant differences in the endoscopic findings between the two groups.

Five patients dropped out due to non-compliance before the final evaluation: three patients due to side effects (one from group A and two from group B) and two patients due to personal reasons. A further 10 patients from each group did not appear at the first visit after completion of therapy or for the <sup>13</sup>C-urea breath test; therefore, they were lost to follow-up (Figure 1).

After the completion of therapy, 194/257 (75.5%) patients tested negative for *H pylori* on the <sup>13</sup>C-urea breath test. ITT analysis showed that *H pylori* was eradicated in 93/129 (72.1%) patients from group A and in 101/128 (78.9%) patients from group B ( $P = 0.204$ ). PP analysis showed successful eradication in 93/118 (78.8%) patients from group A and 101/114 (88.6%) patients from group B (Table 2,  $P = 0.044$ ).

There were no significant differences in the side effects experienced by the patients in the two treatment groups: 26/119 (21.8%) patients in group A and 24/118 (20.3%) patients in group B reported adverse effects due to therapy (Table 3,  $P = 0.776$ ). More patients in group A complained of a metallic taste than in group B (11.8% vs 4.2%,  $P = 0.033$ ). All the side effects were self-limiting and disappeared once therapy was terminated.

## DISCUSSION

Reports about failed *H pylori* eradication therapy have been increasing<sup>[14,15]</sup>. A recent meta-analysis has demonstrated that a 1-wk course of triple therapy with amoxicillin, clarithromycin and a proton pump inhibitor had a pooled eradication rate of 74%-76% or less<sup>[2,16]</sup>. A disappointing cure rate of < 80% after 7 d triple therapy was confirmed in the present study.

Various studies are under way to evaluate new antibiotics (e.g., levofloxacin, moxifloxacin, furazolidone and rifabutin) and different therapeutic schedules to increase the efficacy of *H pylori* eradication therapy<sup>[17-20]</sup>. Data suggest that antibiotic resistance is frequent and clinicians

**Table 2** ITT and PP analysis of *H pylori* eradication in patients who were randomly assigned to standard triple therapy (group A) or triple therapy plus ecabets sodium (group B)

	Group A	Group B	P value
Eradication rate			
ITT <sup>1</sup>	72.1% (93/129)	78.9% (101/128)	0.204
PP	78.8% (93/118)	88.6% (101/114)	0.044

<sup>1</sup>In this analysis, the patients with unknown outcome were counted as treatment failures.

**Table 3** Side effects during standard triple therapy (group A) and triple therapy plus ecabets sodium (group B)

Side effects	Group A	Group B	P value
Metallic taste	14	5	0.033
Nausea/vomiting	1	4	0.213
Abdominal pain	2	2	1.000
Constipation	1	0	1.000
Diarrhea	7	3	0.333
Dizziness	1	6	0.066
Skin rash	0	3	0.122
Oral mucositis	2	1	1.000
Others	4	7	0.347

are arriving at the conclusion that concurrent therapy with another agent may sometimes be necessary.

Ecabets sodium has local cytoprotective activity for the gastric mucosa, but is not absorbed into the systemic circulation<sup>[21]</sup>. Recent studies have demonstrated that ecabets sodium has anti-*H pylori* activity. *In vitro* studies have shown that ecabets sodium inhibits the urease activity of *H pylori* and its adhesion to the gastric epithelial cells<sup>[5,22]</sup>. In addition, ecabets sodium is reported to have a strong concentration-dependent bactericidal effect on *H. pylori* under acidic conditions<sup>[7]</sup>. Although proton pump inhibitors potently suppress acid secretion, the acid milieu (pH 3-5) is especially maintained during most of the day and night<sup>[23]</sup>. Therefore, several studies have evaluated the usefulness of ecabets sodium for eradication therapy in combination with proton-pump-inhibitor-based therapy<sup>[8,10,12]</sup>.

A comparative study demonstrated an eradication rate of 26% with lansoprazole-based dual therapy with clarithromycin or amoxicillin, whereas the eradication rate achieved by adding ecabets sodium to the same regimen was 79%<sup>[12]</sup>. Another study confirmed the additive effect of ecabets sodium on proton-pump-inhibitor-based dual therapy<sup>[11]</sup>. In addition, a dose-dependent additive effect of ecabets sodium in combination with lansoprazole and amoxicillin has been demonstrated<sup>[10]</sup>.

On the basis of this evidence, we thought it likely that the addition of ecabets sodium to triple therapy contributes to improving the rate of *H pylori* eradication. In fact, in this study, PP analysis showed that triple therapy plus ecabets sodium was more effective than standard triple therapy, although there was no significant difference according to ITT analysis. It is possible that triple therapy plus ecabets sodium provokes a synergistic effect by launching attacks from different directions against *H pylori*, and this may

lead to complete clearance of the bacterial infection. The bactericidal effect of ecabet sodium on clarithromycin- and metronidazole-resistant clinical isolates of *H pylori*<sup>[7]</sup> might also explain the increased eradication rate.

The majority of the recently recommended eradication therapy regimens are 1 wk in duration because these have advantages with respect to compliance and medical cost, with a similar eradication rate<sup>[24]</sup>. A good eradication rate was observed in this study after a 1-wk-long triple therapy plus ecabet sodium.

Because ecabet sodium does not have any systemic activity, it was expected that ecabet sodium-based therapy would be associated with a low occurrence of adverse events. In a previous report, the use of ecabet sodium combined with lansoprazole and amoxicillin reduced the incidence of diarrhea during therapy<sup>[11]</sup>. However, there was no significant difference of adverse events between standard triple therapy and triple therapy plus ecabet sodium in this study. The use of triple therapy plus ecabet sodium reduced the incidence of metallic taste during therapy, and this might have been due to the sweet taste of ecabet sodium.

In recent years, many studies have compared the effectiveness of triple and bismuth quadruple therapy as a primary therapy for *H pylori*<sup>[25-28]</sup>. A recent meta-analysis including five randomized trials has reported slightly higher, but not statistically significant, eradication rates with quadruple therapy: ITT and PP eradication rates were 79% and 85% for clarithromycin triple therapy and 80% and 87% for bismuth quadruple therapy, respectively<sup>[29]</sup>. However, quadruple therapy is complex to take (q.i.d. dosing regimen and high pill count) and has a perceived high frequency of side effects<sup>[30]</sup>.

In conclusion, this randomized prospective study showed (based on PP analysis) that the addition of ecabet sodium improved the efficacy of standard triple therapy for *H pylori* infection. These results need to be confirmed, but triple therapy plus ecabet sodium may represent a valid alternative regimen to the standard *H pylori* eradication protocol.

## COMMENTS

### Background

The eradication rate of *H pylori* by standard triple therapy is only 74%-76%. Ecabet sodium has been reported to exhibit a bactericidal effect against *H pylori* by inhibiting bacterial urease activity or by its direct bactericidal effect. This study compared the efficacy and side effects of standard triple therapy versus triple therapy plus ecabet sodium for the eradication of *H pylori*.

### Research frontiers

Research in this area is focused on developing more effective eradication regimens for *H pylori* infection. Ecabet sodium is widely used for the treatment of gastric ulcer and gastritis in East Asia. Its bactericidal effect on clarithromycin- and metronidazole-resistant clinical isolates of *H pylori* has been reported. Therefore, it is presumed that adding ecabet sodium to standard triple therapy is more efficient for the eradication of *H pylori*. In our randomized prospective study, the addition of ecabet sodium may have improved the efficacy of standard triple therapy for *H pylori*.

### Innovations and breakthroughs

Some reports about the efficacy of ecabet sodium for *H pylori* infection have been reported. But the efficacy and side effects of standard triple therapy plus ecabet sodium have not yet been investigated. By PP analysis, the rate of successful

eradication was 78.8% for standard triple therapy and 88.6% for triple therapy plus ecabet sodium. There were no differences in the side effects in the two treatment groups. These results need to be confirmed, but triple therapy plus ecabet sodium may improve the eradication rate of *H pylori*.

### Applications

This study demonstrated the efficacy of standard triple therapy plus ecabet sodium. Therefore, this may represent a valid alternative regimen to the standard *H pylori* eradication protocol.

### Terminology

Ecabet sodium is a dehydroabietic acid derivative purified from pine resin and one of the local cytoprotective agents for the gastric mucosa. It is now widely used for the treatment of gastric ulcer and gastritis in East Asia. The eradication rate was evaluated for each drug regimen by PP analysis, based on the number of patients who completed the study, and in an ITT analysis that took into account all patients.

### Peer review

This study compared two therapeutic regimens for the cure of *H pylori* infection: a classic triple PPI based therapy vs the same regimen plus ecabet sodium (a natural bactericidal compound). The study was well designed and conducted.

## REFERENCES

- 1 **Malfetheriner P**, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. *Gut* 2007; **56**: 772-781
- 2 **Vergara M**, Vallve M, Gisbert JP, Calvet X. Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. *Aliment Pharmacol Ther* 2003; **18**: 647-654
- 3 **Hunt RH**. Eradication of Helicobacter pylori infection. *Am J Med* 1996; **100**: 42S-50S; discussion 50S-51S
- 4 **Onoda Y**, Magaribuchi T, Tamaki H. Effects of the new anti-ulcer agent 12-sulfodehydroabietic acid monosodium salt on duodenal alkaline secretion in rats. *Arzneimittelforschung* 1990; **40**: 576-578
- 5 **Ito Y**, Shibata K, Hongo A, Kinoshita M. Ecabet sodium, a locally acting antiulcer drug, inhibits urease activity of Helicobacter pylori. *Eur J Pharmacol* 1998; **345**: 193-198
- 6 **Shibata K**, Ito Y, Hongo A, Yasoshima A, Endo T, Ohashi M. Bacterial activity of a new antiulcer agent, ecabet sodium, against Helicobacter pylori under acidic conditions. *Antimicrob Agents Chemother* 1995; **39**: 1295-1299
- 7 **Shibata K**, Kasuga O, Yasoshima A, Matsushita T, Kawakami Y. Bactericidal effect of ecabet sodium on clarithromycin- and metronidazole-resistant clinical isolates of Helicobacter pylori. *Jpn J Antibiot* 1997; **50**: 525-531
- 8 **Shimoyama T**, Fukuda S, Liu Q, Nakaji S, Munakata A, Sugawara K. Ecabet sodium inhibits the ability of Helicobacter pylori to induce neutrophil production of reactive oxygen species and interleukin-8. *J Gastroenterol* 2001; **36**: 153-157
- 9 **Adachi K**, Ishihara S, Hashimoto T, Hirakawa K, Ishimura N, Niigaki M, Kaji T, Kawamura A, Sato H, Fujishiro H, Hattori S, Watanabe M, Kinoshita Y. Efficacy of ecabet sodium for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen. *Aliment Pharmacol Ther* 2001; **15**: 1187-1191
- 10 **Kagaya H**, Kato M, Komatsu Y, Mizushima T, Sukegawa M, Nishikawa K, Hokari K, Takeda H, Sugiyama T, Asaka M. High-dose ecabet sodium improves the eradication rate of helicobacter pylori in dual therapy with lansoprazole and amoxicillin. *Aliment Pharmacol Ther* 2000; **14**: 1523-1527
- 11 **Ohkusa T**, Takashimizu I, Fujiki K, Araki A, Ariake K, Shimoi K, Honda K, Enomoto Y, Sakurazawa T, Horiuchi T, Suzuki S, Ishii K, Ishikura T. Prospective evaluation of a new anti-ulcer agent, ecabet sodium, for the treatment of Helicobacter pylori infection. *Aliment Pharmacol Ther* 1998; **12**: 457-461
- 12 **Shimoyama T**, Fukuda Y, Fukuda S, Munakata A, Yoshida Y, Shimoyama T. Ecabet sodium eradicates Helicobacter pylori



- infection in gastric ulcer patients. *J Gastroenterol* 1996; **31** Suppl 9: 59-62
- 13 **Bielanski W**, Konturek SJ. New approach to 13C-urea breath test: capsule-based modification with low-dose of 13C-urea in the diagnosis of *Helicobacter pylori* infection. *J Physiol Pharmacol* 1996; **47**: 545-553
- 14 **McLoughlin R**, Racz I, Buckley M, O'Connor HJ, O'Morain C. Therapy of *Helicobacter pylori*. *Helicobacter* 2004; **9** Suppl 1: 42-48
- 15 **Fischbach LA**, Goodman KJ, Feldman M, Aragaki C. Sources of variation of *Helicobacter pylori* treatment success in adults worldwide: a meta-analysis. *Int J Epidemiol* 2002; **31**: 128-139
- 16 **Altintas E**, Sezgin O, Ulu O, Aydin O, Camdeviren H. Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating *Helicobacter pylori*. *World J Gastroenterol* 2004; **10**: 1656-1658
- 17 **Rispo A**, Di Girolamo E, Cozzolino A, Bozzi R, Morante A, Pasquale L. Levofloxacin in first-line treatment of *Helicobacter pylori* infection. *Helicobacter* 2007; **12**: 364-365
- 18 **Sezgin O**, Altintas E, Ucbilek E, Tombak A, Tellioglu B. Low efficacy rate of moxifloxacin-containing *Helicobacter pylori* eradication treatment: in an observational study in a Turkish population. *Helicobacter* 2007; **12**: 518-522
- 19 **Daghaghzadeh H**, Emami MH, Karimi S, Raeisi M. One-week versus two-week furazolidone-based quadruple therapy as the first-line treatment for *Helicobacter pylori* infection in Iran. *J Gastroenterol Hepatol* 2007; **22**: 1399-1403
- 20 **Miehlke S**, Hansky K, Schneider-Brachert W, Kirsch C, Morgner A, Madisch A, Kuhlisch E, Bastlein E, Jacobs E, Bayerdorffer E, Lehn N, Stolte M. Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of *Helicobacter pylori* resistant to both metronidazole and clarithromycin. *Aliment Pharmacol Ther* 2006; **24**: 395-403
- 21 **Ito Y**, Sugawara Y, Takaiti O, Nakamura S. Metabolic fate of a new anti-ulcer drug (+)-(1R,4aS,10aR)-1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-6-sulfo-1-phenanthrenecarboxylic acid 6-sodium salt pentahydrate (TA-2711). II. Distribution in the rat stomach. *J Pharmacobiodyn* 1991; **14**: 547-554
- 22 **Fukuda Y**, Yamamoto I, Okui M, Tonokatsu Y, Shimoyama T. Combination therapies with a proton pump inhibitor for *Helicobacter pylori*-infected gastric ulcer patients. *J Clin Gastroenterol* 1995; **20** Suppl 2: S132-S135
- 23 **Bruley des Varannes S**, Levy P, Lartigue S, Dellatolas F, Lemaire M, Galmiche JP. Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion and serum gastrin in healthy volunteers. *Aliment Pharmacol Ther* 1994; **8**: 309-314
- 24 **Fuccio L**, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for *Helicobacter pylori* eradication. *Ann Intern Med* 2007; **147**: 553-562
- 25 **Calvet X**, Ducons J, Guardiola J, Tito L, Andreu V, Bory F, Guirao R. One-week triple vs. quadruple therapy for *Helicobacter pylori* infection - a randomized trial. *Aliment Pharmacol Ther* 2002; **16**: 1261-1267
- 26 **Gomollon F**, Valdeperez J, Garuz R, Fuentes J, Barrera F, Malo J, Tirado M, Simon MA. Cost-effectiveness analysis of 2 strategies of *Helicobacter pylori* eradication: results of a prospective and randomized study in primary care. *Med Clin (Barc)* 2000; **115**: 1-6
- 27 **Laine L**, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spenard J. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of *Helicobacter pylori* in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. *Am J Gastroenterol* 2003; **98**: 562-567
- 28 **Katellaris PH**, Forbes GM, Talley NJ, Crotty B. A randomized comparison of quadruple and triple therapies for *Helicobacter pylori* eradication: The QUADRATE Study. *Gastroenterology* 2002; **123**: 1763-1769
- 29 **Gene E**, Calvet X, Azagra R, Gisbert JP. Triple vs quadruple therapy for treating *Helicobacter pylori* infection: an updated meta-analysis. *Aliment Pharmacol Ther* 2003; **18**: 543-544
- 30 **Chey WD**, Wong BC. American College of Gastroenterology guideline on the management of *Helicobacter pylori* infection. *Am J Gastroenterol* 2007; **102**: 1808-1825

S- Editor Zhu LH L- Editor Kerr C E- Editor Wang HF